PROGLUMETACIN MALEATE

Product NamePROGLUMETACIN MALEATE
CAS57132-53-3
MFC46H58ClN5O8
MW844.43
EINECS
MOL File57132-53-3.mol

Chemical Properties

solubility	DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
form	Solid
color	White to Pale Yellow

Usage And Synthesis

Uses

Proglumetacin Dioxalate is a new non-steroidal anti-inflammatory drug.

Definition

ChEBI: A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N2-benzoyl-N,N-dipropy -alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretor effects that helps prevent injury to the stomach lining.

Synthesis

The reaction of N-benzoyl-N_x0002_, N_x0002_-di-n-propyl-dl-isoglutamin (proglumide) with 1-(3-chloropropyl)-4-(2-hydroxyethyl)-piperazine obtained from 1-(2-hydroxyethyl)piperazine and 1-bromo-3-chloropropane by means of sodium methanolate in DMSO at 105C gives N--N_x0002_-(2-hydroxyethyl) piperazine, which is then condensated with Indomethacin (1-(p-chlorobenzoyl)- 5-methoxy-2-methylindole-3-acetic acid) by means of dicyclohexylcabodiimide and NaHCO3 in ethyl acetate .
Synthesis_57132-53-3

in vivo

Proglumetacin (Sprague-Dawley rats, 0-30 mg/kg, Orally, once) dose-dependently inhibits accumulation of pouch exudate^[1].

Animal Model:	Sprague-Dawley rats (6 weeks)
Dosage:	0, 0.3, 3, 9, 30 mg/kg
Administration:	Orally, once
Result:	Caused dose-dependent reduction of leukocyte migration into the pouch exudate, caused 49.2% inhibition at 30 mg/kg; and markedly decreased the prostaglandin E₂ content of the pouch exudate, but tended to increase the leukotriene B₄ content.